Halozyme Announces Roche Receives Marketing Authorization for Herceptin SC in EU

Halozyme Therapeutics, Inc. (NASDAQ: HALO ) announced today that the European Commission has granted Roche (OTC: RHHBY ) European Union (EU) marketing authorization for the use of a time-saving subcutaneous (SC) formulation of Herceptin® (trastuzumab) for the treatment of HER2-positive breast cancer. This formulation utilizes Halozyme's recombinant human